Magnetic nanoparticle hyperthermia potentiates paclitaxel activity in sensitive and resistant breast cancer cells

Introduction Overcoming resistance to antimitotic drugs, such as paclitaxel (PTX), would represent a major advance in breast cancer treatment. PTX induces mitotic block and sensitive cells exit mitosis dying by mitotic catastrophe. Resistant cells remain in block and continue proliferation after drug decay, denoting one of the PTX resistance mechanisms. Mild hyperthermia (HT) triggers mitotic exit of PTX-pretreated cells, overcoming PTX resistance and suggesting HT-forced mitotic exit as a promising strategy to potentiate PTX. Methods and results Superparamagnetic iron oxide nanoparticles (SPIONs) were used to deliver mild HT at 42°C in PTX-pretreated breast adenocarcinoma MCF-7 cells sensitive and resistant to PTX. To evaluate mechanism of cell death, cells were classified based on nuclear morphology into interphase, mitotic, micronucleated, and apoptotic. The combined PTX→SPION treatment resulted in an increase in the percentage of micronucleated cells, an indication of forced mitotic exit. Importantly, in PTX-resistant cells, the combination therapy using SPION HT helps to overcome resistance by reducing the number of cells relative to the control. Conclusion SPION HT potentiates PTX by significantly reducing cell survival, suggesting potential of combined treatment for future clinical translation.

[1]  Zhi Wei Tay,et al.  Combining magnetic particle imaging and magnetic fluid hyperthermia in a theranostic platform , 2017, Physics in medicine and biology.

[2]  L. Kourkoutis,et al.  Thermal Decomposition Synthesis of Iron Oxide Nanoparticles with Diminished Magnetic Dead Layer by Controlled Addition of Oxygen. , 2017, ACS nano.

[3]  C. Rinaldi,et al.  Theoretical Predictions for Spatially-Focused Heating of Magnetic Nanoparticles Guided by Magnetic Particle Imaging Field Gradients. , 2016, Journal of magnetism and magnetic materials.

[4]  Carlos Rinaldi,et al.  Estimating the contribution of Brownian and Néel relaxation in a magnetic fluid through dynamic magnetic susceptibility measurements , 2016 .

[5]  L. Pericchi,et al.  Optimization of synthesis and peptization steps to obtain iron oxide nanoparticles with high energy dissipation rates. , 2015, Journal of magnetism and magnetic materials.

[6]  Diane D. Liu,et al.  Treatment of carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in adolescents and young adults. , 2015, American journal of surgery.

[7]  M. Torres-Lugo,et al.  Enhanced proteotoxic stress: one of the contributors for hyperthermic potentiation of the proteasome inhibitor bortezomib using magnetic nanoparticles. , 2015, Biomaterials science.

[8]  B. Weaver,et al.  How Taxol/paclitaxel kills cancer cells , 2014, Molecular biology of the cell.

[9]  R. Bristow,et al.  Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise , 2014, Current Treatment Options in Oncology.

[10]  M. Torres-Lugo,et al.  Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines , 2013, International journal of nanomedicine.

[11]  C. Rinaldi,et al.  Magnetic fluid hyperthermia: Advances, challenges, and opportunity , 2013, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[12]  Carlos Rinaldi,et al.  Thermal potentiation of chemotherapy by magnetic nanoparticles. , 2013, Nanomedicine.

[13]  A. M. Ishov,et al.  Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy , 2013, Cell cycle.

[14]  M. Torres-Lugo,et al.  Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. , 2013, ACS nano.

[15]  P. Giannakakou,et al.  Androgen receptor on the move: boarding the microtubule expressway to the nucleus. , 2012, Cancer research.

[16]  S. Mulier,et al.  Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. , 2012, Current pharmaceutical design.

[17]  Sumit Arora,et al.  Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers , 2012, International journal of nanomedicine.

[18]  Carlos Rinaldi,et al.  Effect of poly(ethylene oxide)-silane graft molecular weight on the colloidal properties of iron oxide nanoparticles for biomedical applications. , 2012, Journal of colloid and interface science.

[19]  R. Wäsch,et al.  Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations , 2012, Cell cycle.

[20]  Carlos Rinaldi,et al.  EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. , 2011, ACS nano.

[21]  Morteza Mahmoudi,et al.  Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. , 2011, Advances in colloid and interface science.

[22]  R. Medema,et al.  Mitosis as an anti-cancer target , 2011, Oncogene.

[23]  M. Torres-Lugo,et al.  Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. , 2011, Journal of nanoscience and nanotechnology.

[24]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[25]  M. Torres-Lugo,et al.  The effect of grafting method on the colloidal stability and in vitro cytotoxicity of carboxymethyl dextran coated magnetic nanoparticles , 2010 .

[26]  P. Wust,et al.  Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme , 2010, Journal of Neuro-Oncology.

[27]  E. Atalar,et al.  Focused RF hyperthermia using magnetic fluids. , 2009, Medical physics.

[28]  Baoqing Guo,et al.  Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance , 2008, BMC Cancer.

[29]  B. Zhivotovsky,et al.  Death through a tragedy: mitotic catastrophe , 2008, Cell Death and Differentiation.

[30]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[31]  H. Broxmeyer,et al.  Cells enter a unique intermediate 4N stage, not 4N-G1, after aborted mitosis , 2008, Cell cycle.

[32]  Jean-Paul Fortin,et al.  Intracellular heating of living cells through Néel relaxation of magnetic nanoparticles , 2008, European Biophysics Journal.

[33]  A. Jordan,et al.  Clinical applications of magnetic nanoparticles for hyperthermia , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[34]  A. M. Ishov,et al.  Daxx Shortens Mitotic Arrest Caused by Paclitaxel , 2007, Cell cycle.

[35]  E. Salmon,et al.  The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.

[36]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[37]  Michael O'Leary,et al.  Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. , 2004, The oncologist.

[38]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[39]  I. Roninson,et al.  If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  G. Selivanova,et al.  ARREST IN METAPHASE AND ANATOMY OF MITOTIC CATASTROPHE: MILD HEAT SHOCK IN TWO HUMAN OSTEOSARCOMA CELL LINES , 2000, Cell biology international.

[41]  M. Namer,et al.  Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. , 1999, European journal of cancer.

[42]  P. Wust,et al.  Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles , 1999 .

[43]  C. Rinaldi,et al.  Colloidal dispersions of monodisperse magnetite nanoparticles modified with poly(ethylene glycol). , 2009, Journal of colloid and interface science.

[44]  J. Zee Heating the patient : a promising approach ? , 2002 .

[45]  S. Loening,et al.  Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia , 2001 .